The effect of simvastatin on oxidative stress and inflammatory reaction in patients with moderate to severe chronic obstructive pulmonary disease
10.3969/j.issn.1006-5725.2017.21.030
- VernacularTitle:斯伐他汀对稳定期中重度慢性阻塞性肺病患者炎症因子及肺功能的影响
- Author:
Lei LI
1
;
Zhengyi NI
;
Zhongwen TANG
;
Mi ZHOU
Author Information
1. 430000,武汉市医疗救治中心外一科
- Keywords:
COPD;
simvastatin;
IL-6;
TNF-α;
Hs-CRP;
MRC score
- From:
The Journal of Practical Medicine
2017;33(21):3619-3622
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effect of simvastatin on oxidative stress and inflammatory reac-tion in patients with stable moderate to severe chronic obstructive pulmonary disease and its mechanism. Meth-ods Sixty patients diagnosed with chronic obstructive pulmonary disease were randomly divided into the simvas-tatin group and the placebo group.The simvastatin group was treated with simvastatin in 40 mg/d for 12 weeks,and the placebo group with placebo.The general clinical features,the concentration of inflammatory factors,pulmonary function,6-minute walk test and MRC score were compared between the two groups.Results There was no signif-icant difference between these two groups in basic features. There was a decrease of IL-6,TNF-a and Hs-CRP in concentration in the simvastatin group after treatment. which was significantly lower than that of the placebo group after treatment.The 6-minute walk test in the simvastatin group was much better than that in the placebo group(P=0.00).MRC score was improved compared with therapy before(P=0.02).There was no significantly difference in 6-minute walk test and MRC score before and after treatment in the placebo group(P=0.81). The PaO2 was im-proved after treatment in the simvastatin group compared with therapy before and that in the placebo group after therapy(P<0.05)respectively.There was no significantly difference in FEV1and FVC between these two groups. Conclusion Simvastatin can decrease the concentration of inflammatory factors in stable moderate to severe chron-ic obstructive pulmonary disease,and improve the pulmonary function.
